EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

NCT06997588 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

PIK3CA-related Overgrowth Spectrum (PROS)

Interventions

DRUG: Alpelisib

Sponsor

Novartis Pharmaceuticals